切换至 "中华医学电子期刊资源库"

中华临床医师杂志(电子版) ›› 2026, Vol. 20 ›› Issue (06) : 479 -486. doi: 10.3877/cma.j.issn.1674-0785.2026.06.009

综述

免疫联合策略在MSS/pMMR型结直肠癌转化治疗中的探索
张建锋1, 赵泽铭2, 武雪亮3, 马洪庆1, 王贵英1,2,†()   
  1. 1 050001 石家庄,河北医科大学第四医院外二科
    2 050000 石家庄,河北医科大学第二医院普外科
    3 075132 张家口,河北北方学院附属第一医院
  • 收稿日期:2026-05-04 出版日期:2026-06-30
  • 通信作者: 王贵英
  • 基金资助:
    河北省卫健委医学科学课题(20260505); 中华国际科学交流基金会医学科学技术发展专项基金生物医药创新发展科技科研项目(SWYY2025003040)

Immune combination strategies in conversion therapy for microsatellite stable/mismatch repair proficient colorectal cancer

Jianfeng Zhang1, Zeming Zhao2, Xueliang Wu3, Hongqing Ma1, Guiying Wang1,2,†()   

  1. 1 The Second Department of Surgery of the Fourth Hospital of Hebei Medical University, Shijiazhuang 050001, China
    2 Department of General Surgery, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China
    3 The First Hospital Affiliated to Hebei North University, Zhangjiakou 075132, China
  • Received:2026-05-04 Published:2026-06-30
  • Corresponding author: Guiying Wang
引用本文:

张建锋, 赵泽铭, 武雪亮, 马洪庆, 王贵英. 免疫联合策略在MSS/pMMR型结直肠癌转化治疗中的探索[J/OL]. 中华临床医师杂志(电子版), 2026, 20(06): 479-486.

Jianfeng Zhang, Zeming Zhao, Xueliang Wu, Hongqing Ma, Guiying Wang. Immune combination strategies in conversion therapy for microsatellite stable/mismatch repair proficient colorectal cancer[J/OL]. Chinese Journal of Clinicians(Electronic Edition), 2026, 20(06): 479-486.

结直肠癌(CRC)是我国发病率居前的恶性肿瘤,约80%-85%病例为微卫星稳定(MSS)/错配修复功能正常(pMMR)亚型,其对免疫检查点抑制剂(ICIs)单药响应率低,是CRC免疫转化治疗领域的主要挑战。近年,随着对肿瘤免疫微环境(TIME)“冷-热” 转化机制认识的深入,以ICIs为基础的免疫联合策略(联合靶向、化疗或抗血管生成药物)在临床研究中显示逆转免疫耐药潜力,为MSS/pMMR型CRC转化治疗提供新证据。本文聚焦外科治疗的临床视角出发,系统梳理各类ICIs联合策略的作用机制与临床研究进展,重点探讨其在疗效评估、手术时机选择、围手术期安全管理等方面的关键科学问题,并展望了基于精准医学的个体化治疗及多学科协作(MDT)的未来发展方向,旨在为MSS/pMMR型CRC转化治疗临床实践与科研探索提供参考。

Colorectal cancer is one of the most common malignancies in China, with approximately 80%-85% of cases classified as microsatellite stable/mismatch repair proficient (MSS/pMMR). This subtype exhibits a low response rate to immune checkpoint inhibitor (ICI) monotherapy, posing a major challenge in the field of CRC immunotherapeutic conversion. Recent advances in understanding the conversion mechanisms of the tumor immune microenvironment from a "cold" to a "hot" state have facilitated the development of ICI-based combination strategies. These include regimens that incorporate targeted therapies, chemotherapy, or anti-angiogenic agents, which have shown promise in overcoming immune resistance in clinical studies and offer new avenues for converting MSS/pMMR CRC. From a clinical perspective with an emphasis on surgical treatment, this article systematically reviews the mechanisms and clinical progress of various ICI combination strategies. It discusses key scientific issues such as efficacy evaluation, optimal timing of surgery, and perioperative safety management, while also exploring future directions for precision medicine and multidisciplinary team collaboration. The review aims to provide valuable insights for both clinical practice and research in the conversion therapy of MSS/pMMR colorectal cancer.

1
中国抗癌协会, 中国抗癌协会大肠癌专业委员会. 中国恶性肿瘤整合诊治指南-直肠癌(2024 版) [J]. 中华结直肠疾病电子杂志, 2025, 14(1): 1-19.
2
André T, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy in microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer: 5-year follow-up from the randomized phase Ⅲ KEYNOTE-177 study [J]. Ann Oncol, 2025, 36(3): 277-284.
3
André T, Shiu KK, Kim TW, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer [J]. N Engl J Med, 2020, 383(23): 2207-2218.
4
Williams CJM, Peddle AM, Kasi PM, et al. Neoadjuvant immunotherapy for dMMR and pMMR colorectal cancers: therapeutic strategies and putative biomarkers of response [J]. Nat Rev Clin Oncol, 2024, 21(12): 839-851.
5
Zhang Y, Wang D, Zhang K, et al. First-line treatment with a combination of immunotherapy, anti-EGFR monoclonal antibodies, and chemotherapeutics for unresectable left KRAS/BRAF wild-type microsatellite-stable colorectal cancer: a case report [J]. Anticancer Drugs, 2025, 36(8): 686-690.
6
Bullock AJ, Schlechter BL, Fakih MG, et al. Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial [J]. Nat Med, 2024, 30(9): 2558-2567.
7
Galon J, Bruni D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies [J]. Nat Rev Drug Discov, 2019, 18(3): 197-218.
8
Lin KX, Istl AC, Quan D, et al. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies [J]. Cancer Immunol Immunother, 2023, 72(12): 3875-3893.
9
Al Zein M, Boukhdoud M, Shammaa H, et al. Immunotherapy and immunoevasion of colorectal cancer [J]. Drug Discov Today, 2023, 28(9): 103669.
10
Yu H, Liu S, Yuan Z, et al. Targeted co-delivery of rapamycin and oxaliplatin by liposomes suppresses tumor growth and metastasis of colorectal cancer [J]. Biomed Pharmacother, 2024, 178: 117192.
11
Pozzi C, Cuomo A, Spadoni I, et al. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death [J]. Nat Med, 2016, 22(6): 624-631.
12
Feng Y, Ma W, Zang Y, et al. Spatially organized tumor-stroma boundary determines the efficacy of immunotherapy in colorectal cancer patients [J]. Nat Commun, 2024, 15(1): 10259.
13
Xie YH, Chen YX, Fang JY. Comprehensive review of targeted therapy for colorectal cancer [J]. Signal Transduct Target Ther, 2020, 5(1): 22.
14
Pavelescu LA, Enache RM, Roşu OA, et al. Predictive biomarkers and resistance mechanisms of checkpoint inhibitors in malignant solid tumors [J]. Int J Mol Sci, 2024, 25(17): 9659.
15
Yang X, Yan Y, Wang F, et al. Aspirin prevents colorectal cancer by regulating the abundance of Enterococcus cecorum and TIGIT(+)Treg cells [J]. Sci Rep, 2024, 14(1): 13592.
16
曹飞, 庞俊. 前列腺癌免疫微环境中免疫抑制性细胞分类及其作用机制[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(2): 121-125.
17
Gomez-Roca C, Cassier P, Zamarin D, et al. Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade [J]. J Immunother Cancer, 2022, 10(5): e004076.
18
Sung E, Ko M, Won JY, et al. LAG-3xPD-L1 bispecific antibody potentiates antitumor responses of T cells through dendritic cell activation [J]. Mol Ther, 2022, 30(8): 2800-2816.
19
Zhang Y, Chen H, Mo H, et al. Distinct cellular mechanisms underlie chemotherapies and PD-L1 blockade combinations in triple-negative breast cancer [J]. Cancer Cell, 2025, 43(3): 446-463.e7.
20
Su C, Liao Z, Mo J, et al. VRK2 targeting potentiates anti-PD-1 immunotherapy in hepatocellular carcinoma through MYC destabilization [J]. Nat Commun, 2025, 16(1): 9027.
21
Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies [J]. Cancer Immunol Res, 2015, 3(5): 436-443.
22
Xue J, Yu X, Xue L, et al. Intrinsic β-catenin signaling suppresses CD8(+) T-cell infiltration in colorectal cancer [J]. Biomed Pharmacother, 2019, 115: 108921.
23
Toulmonde M, Guégan JP, Spalato-Ceruso M, et al. Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab [J]. Signal Transduct Target Ther, 2025, 10(1): 202.
24
苏燕燕, 杨翀, 张宗祥, 等. 瑞戈非尼通过CSF1-R信号通路调节肿瘤相关巨噬细胞增强PD-1抗体在结直肠癌中疗效的研究 [J]. 浙江中西医结合杂志, 2023, 33(10): 909-914.
25
Jiang M, Chen P, Wang L, et al. cGAS-STING, an important pathway in cancer immunotherapy [J]. J Hematol Oncol, 2020, 13(1): 81.
26
Zhigarev D, Varshavsky A, MacFarlane AW 4th, et al. Lymphocyte exhaustion in AML patients and impacts of HMA/venetoclax or intensive chemotherapy on their biology [J]. Cancers (Basel), 2022, 14(14): 3352.
27
Galluzzi L, Humeau J, Buqué A, et al. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors [J]. Nat Rev Clin Oncol, 2020, 17(12): 725-741.
28
Lenz HJ, Parikh A, Spigel DR, et al. Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial [J]. J Immunother Cancer, 2024, 12(3): e008409.
29
Antoniotti C, Rossini D, Pietrantonio F, et al. Upfront fluorouracil, leucovorin, oxaliplatin, and irinotecan plus bevacizumab with or without atezolizumab for patients with metastatic colorectal cancer: updated and overall survival results of the ATEZOTRIBE study [J]. J Clin Oncol, 2024, 42(22): 2637-2644.
30
Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase Ib trial (REGONIVO, EPOC1603) [J]. J Clin Oncol, 2020, 38(18): 2053-2061.
31
Fakih M, Sandhu J, Lim D, et al. Regorafenib, ipilimumab, and nivolumab for patients with microsatellite stable colorectal cancer and disease progression with prior chemotherapy: A phase 1 nonrandomized clinical trial [J]. JAMA Oncol, 2023, 9(5): 627-634.
32
Nie C, Lv H, Chen B, et al. Microsatellite stable metastatic colorectal cancer without liver metastasis may be preferred population for regorafenib or fruquintinib plus sintilimab as third-line or above therapy:A real-world study [J]. Front Oncol, 2022, 12: 917353.
33
Tian J, Chen JH, Chao SX, et al. Combined PD-1, BRAF and MEK inhibition in BRAF(V600E) colorectal cancer: a phase 2 trial [J]. Nat Med, 2023, 29(2): 458-466.
34
Wang F, Zhao Q, Wang YN, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types [J]. JAMA Oncol, 2019, 5(10): 1504-1506.
35
El Hajj J, Reddy S, Verma N, et al. Immune checkpoint inhibitors in pMMR/MSS colorectal cancer [J]. J Gastrointest Cancer, 2023, 54(4): 1017-1030.
36
Kim R, Tehfe M, Kavan P, et al. Pembrolizumab plus mFOLFOX7 or FOLFIRI for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer: KEYNOTE-651 cohorts B and D [J]. Clin Colorectal Cancer, 2024, 23(2): 118-127.e6.
37
Fang X, Zhong C, Weng S, et al. Sintilimab plus bevacizumab and CapeOx (BBCAPX) on first-line treatment in patients with RAS mutant, microsatellite stable, metastatic colorectal cancer: study protocol of a randomized, open-label, multicentric study [J]. BMC Cancer, 2023, 23(1): 676.
38
Wang L, Zhang T, Pan Q, et al. A phase Ⅱ study to evaluate the efficacy and safety of fruquintinib combined with tislelizumab and hepatic artery infusion chemotherapy (HAIC) for advanced colorectal cancer liver metastases: An updated analysis of survival [J]. J Clin Oncol, 2024, 42(16_suppl): 3543-3543.
39
Wang Z, Ouyang H, Luo H, et al. A phase Ⅱ clinical evaluation of radiofrequency ablation (RFA) combined with regorafenib and toripalimab in patients with colorectal cancer with liver metastases [J]. J Clin Oncol, 2024, 42(16_suppl): 3566-3566.
40
Wu C, Shao Y, Gu W. Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer [J]. Clin Transl Oncol, 2023, 25(7): 1916-1928.
41
Zhou P, Wang Y, Qin S, et al. Abscopal effect triggered by radiation sequential mono-immunotherapy resulted in a complete remission of PMMR sigmoid colon cancer [J]. Front Immunol, 2023, 14: 1139527.
42
Zhang Y, Guan H, Liu S, et al. Gamma knife stereotactic radiotherapy combined with tislelizumab as later-line therapy in pMMR/MSS/MSI-L metastatic colorectal cancer: a phase II trial analysis [J]. Elife, 2025, 14: RP103559.
43
Ni J, Wan CG, Sui ZQ. Efficacy and safety of radiotherapy in patients with microsatellite stable or proficient mismatch repair colorectal cancer liver metastasis [J]. World J Gastrointest Oncol, 2025, 17(3): 102873.
44
He F, Yao Q, Pei F, et al. Stereotactic body radiotherapy combined with PD-1 antibody in unresectable colorectal liver metastases: A prospective, multicenter, single-arm, phase Ⅱ study (SPARKLE-L) [J]. J Clin Oncol, 2025, 43(16_suppl): TPS3639-TPS.
45
Li X, Shan Z, Shen L, et al. 146TiP MIRACLE3: Phase Ⅱ study of ivonescimab plus radiotherapy and chemotherapy as first-line treatment in MSS colorectal cancer patients with unresectable liver/lung metastases [J]. Annals of Oncology, 2025, 36: S61.
46
Wang F, Jin Y, Wang M, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial [J]. Nat Med, 2024, 30(4): 1035-1043.
47
Morano F, Raimondi A, Pagani F, et al. Temozolomide followed by combination with low-dose ipilimumab and nivolumab in patients with microsatellite-stable, O(6)-methylguanine-DNA methyltransferase-silenced metastatic colorectal cancer: The MAYA trial [J]. J Clin Oncol, 2022, 40(14): 1562-1573.
48
Dai T, Sun H, Liban T, et al. A novel anti-LAG-3/TIGIT bispecific antibody exhibits potent anti-tumor efficacy in mouse models as monotherapy or in combination with PD-1 antibody [J]. Sci Rep, 2024, 14(1): 10661.
49
Guo L, Hu C, Liu Y, et al. Directed natural evolution generates a next-generation oncolytic virus with a high potency and safety profile [J]. Nat Commun, 2023, 14(1): 3410.
50
Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics [J]. Lancet Oncol, 2017, 18(3): e143-e52.
51
中华医学会外科学分会结直肠外科学组, 中国研究型医院学会结直肠肛门外科专委会, 中国结直肠临床研究协作组. 错配修复功能完整和(或)微卫星稳定型局部进展期直肠癌患者短程放疗序贯化疗联合免疫治疗的新辅助治疗专家共识(2025版) [J]. 实用肿瘤杂志, 2025, 40(5): 391-399.
52
Sun HC, Zhou J, Wang Z, et al. Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition) [J]. Hepatobiliary Surg Nutr, 2022, 11(2): 227-252.
53
Zhao G, Zhang H, Xu F, et al. Neoadjuvant pembrolizumab and chemotherapy in resectable clinical stage Ⅲ non-small-cell lung cancer: a retrospective cohort study [J]. Transl Lung Cancer Res, 2023, 12(1): 141-149.
54
Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial [J]. Lancet, 2013, 381(9863): 303-312.
55
Rached L, Laparra A, Sakkal M, et al. Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations [J]. Cancer Treat Rev, 2024, 127: 102751.
56
Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade [J]. N Engl J Med, 2018, 378(2): 158-168.
57
Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase Ⅲ trial after a median follow-up of 11 years [J]. J Clin Oncol, 2012, 30(16): 1926-1933.
58
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J]. Lancet, 2014, 384(9938): 164-172.
59
Fokas E, Liersch T, Fietkau R, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO/ARO/AIO-94 trial [J]. J Clin Oncol, 2014, 32(15): 1554-1562.
60
Chen B, Zhao H, Huang J, et al. Efficacy of regorafenib combined with PD-1 inhibitors in elderly patients with advanced metastatic colorectal cancer [J]. BMC Geriatr, 2022, 22(1): 987.
[1] 中华医学会外科学分会腹腔镜与内镜外科学组, 中国抗癌协会胃癌专业委员会, 中国抗癌协会腔镜与机器人外科分会, 《中华消化外科杂志》编辑委员会. 精准外科胃癌转化治疗专家共识(2025 版)[J/OL]. 中华普通外科学文献(电子版), 2025, 19(03): 145-156.
[2] 赵海涛. 进展期胆管癌治疗探索及展望[J/OL]. 中华普通外科学文献(电子版), 2025, 19(02): 110-110.
[3] 李海波, 罗正宇, 武国. 转化治疗后手术切除联合术中消融治疗CNLC Ⅲa期肝细胞癌伴门静脉癌栓一例报告[J/OL]. 中华普外科手术学杂志(电子版), 2026, 20(05): 509-510.
[4] 张珅瑜, 王继洲. 多灶性肝细胞癌的手术策略——外科医师视角[J/OL]. 中华腔镜外科杂志(电子版), 2025, 18(05): 264-270.
[5] 罗希, 汤永生, 鲁旭, 李华. 免疫时代中晚期肝癌治疗新格局:联合策略、转化突破与精准预测[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(04): 508-514.
[6] 张龙, 徐伟, 孙善柯, 李文柱, 李俊达, 池涌泉, 宋进华, 王学浩, 成峰, 饶建华. 载药微球经动脉栓塞化疗在巨块型肝癌转化治疗中的疗效及安全性[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 28-35.
[7] 刘建平, 姚灿开. 肝癌转化治疗策略选择和手术时机[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 16-20.
[8] 杨宇尘, 陈拥军. 三维可视化技术在肝癌转化治疗辅助决策中的应用[J/OL]. 中华肝脏外科手术学电子杂志, 2026, 15(01): 10-15.
[9] 黄少坚, 梁汉标, 李清平, 唐善华, 李青妍, 李芷西, 黄灿, 王小振, 陈灿辉, 王恺, 李川江. 基于影像组学和临床特征构建肝癌新辅助/转化治疗后病理学完全缓解预测模型[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(06): 860-867.
[10] 胡铭语, 李敬东, 肖雨竹, 黄杰. 初始不可切除肝癌患者转化治疗序贯手术的临床疗效分析[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(05): 754-760.
[11] 张宏斌, 杨振宇, 谭凯, 刘冠, 尚磊, 杜锡林. 不可切除肝癌转化治疗后手术的影响因素及预测模型构建[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(03): 387-394.
[12] 颜军, 郭诗翔, 吴堃. 新辅助治疗后“二步法”改良Appleby 术治疗局部进展期胰体癌[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 274-280.
[13] 杨陈凤麟, 张潇, 丁洁茹, 胡文, 李尧, 陈品初, 王泽桐, 张起帆. 转化治疗后肝癌肝切除患者术后自发性胆漏发生原因初步探讨[J/OL]. 中华肝脏外科手术学电子杂志, 2025, 14(02): 256-261.
[14] 王开宇, 张睿, 金号然, 马作红, 李昕, 张雷, 杨卓, 刘也夫, 李娜. 机器人直肠癌肝转移同期切除NOSES手术一例(附视频)[J/OL]. 中华结直肠疾病电子杂志, 2026, 15(01): 92-96.
[15] 王开宇, 郭天宇, 李娜, 白静慧, 张雷, 金号然, 张睿, 刘也夫. 机器人辅助腹腔镜左半结肠切除联合肝右后叶转移瘤切除一例(附视频)[J/OL]. 中华结直肠疾病电子杂志, 2025, 14(02): 189-192.
阅读次数
全文


摘要


AI
小
编
AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?